CD44 and neoplasm: In future studies, an intravenous dose of nCaPCMHACDDP at the maximum tolerable dose with optimized cell uptake and tumor infiltration should be examined in vivo to evaluate the targeting of therapy resistant CD44+ cells by chemically modified HA.